本帖最后由 老马 于 2012-1-13 21:20 编辑
0 Q% h* ?" F$ {# z2 ~; D. c3 a' _ z8 x* W# x K: X
爱必妥和阿瓦斯丁的比较- r3 ^- m0 h5 m
! q) s M/ y6 L: ]; ]http://cancergrace.org/lung/2008/08/30/bms099-os-neg/
" b1 _9 Y/ j. O, n: i
5 M* d7 c+ d" l$ L# ]' O; a
2 B3 Y7 U) N- f* l' Z% f6 U5 H) h
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
+ q% ^' P) L( Q! F==================================================% ]2 l8 Q: d: i$ @) L+ g0 W- a
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
4 a% Z/ S* W6 W; u7 f5 KPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
7 h9 ?9 V3 W# h+ V- x; LResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.. D! h/ r( ?- x. N+ N7 I3 @ h, r
|